Your browser doesn't support javascript.
Шоу: 20 | 50 | 100
Результаты 1 - 4 de 4
Фильтр
Добавить фильтры

Годовой диапазон
1.
Tommaso Francesco Aiello; Jon Salmanton-Garcia; Francesco Marchesi; Barbora Weinbergerova; Andreas Glenthoj; Jens Van Praet; Francesca Farina; Julio Davila-Valls; Sonia Martín-Pérez; Shaimaa El-Ashwah; Martin Schönlein; Iker Falces-Romero; Jorge Labrador; Uluhan Sili; Caterina Buquicchio; Antonio Vena; Gaetan Plantefeve; Verena Petzer; Monika M. Biernat; Tobias Lahmer; Ildefonso Espigado; Jaap A. van Doesum; Ola Blennow; Klára Piukovics; Carlo Tascini; Michael Samarkos; Yavuz M. Bilgin; Luana Fianchi; Federico Itri; Toni Valkovic; Nicola S. Fracchiolla; Michelina Dargenio; Moraima Jimenez; Ferenc Magyari; Alberto Lopez-Garcia; Lucia Prezioso; Natasa Čolovic; Evgenii Shumilov; Ghaith Abu-Zeinah; Esperanza Lavilla-Rubira; Mario Virgilio Papa; Tomás-José Lopez-Gonzalez; László Imre Pinczes; Fatih Demirkan; Natasha Ali; Caroline Besson; Guillemette Fouquet; Alessandra Romano; Jose Angel Hernández-Rivas; Maria Ilaria del Principe; Avinash Aujayeb; Maria Merelli; Sylvain Lamure; Joyce Marques De Almeida; Maria Gomes da Silva; Noha Eisa; Joseph Meletiadis; Ikhwan Rinaldi; Olimpia Finizio; Ozren Jakšić; Mario Delia; Summiya Nizamuddin; Monia Marchetti; Marina Machado; Martin Cernan; Nicola Coppola; Eleni Gavriilaki; Chiara Cattaneo; Ana Groh; Zlate Stojanoski; Nurettin Erben; Nikola Pantic; Gustavo-Adolfo Mendez; Roberta Di Blasi; Stef Meers; Cristina De Ramon; Nathan C. Bahr; Ziad Emarah; Gina Varricchio; Milche Cvetanoski; Ramón Garcia-Sanz; Mirjana Mitrovic; Raphaël Lievin; Michaela Hanakova; Zdeněk Racil; Maria Vehreschild; Athanasios Tragiannidis; Raquel Nunes Rodrigues; Daniel Garcia-Bordallo; Raul Cordoba; Alba Cabirta; Anna Nordlander; Emanuele Ammatuna; Elena Arellano; Dominik Wolf; Romane Prin; Alessandro Limongelli; Martina Bavastro; Gökçe Melis Çolak; Stefanie K. Grafe; Ditte Stampe Hersby; Laman Rahimli; Oliver A. Cornely; Carolina Garcia-Vidal; Livio Pagano.
ssrn; 2023.
Препринт в английский | PREPRINT-SSRN | ID: ppzbmed-10.2139.ssrn.4473151
3.
Francesco Marchesi; Jon Salmanton-Garcia; Ziad EMARAH; Klára PIUKOVICS; Marcio Nucci; Alberto Lopez-Garcia; Zdenek Racil; Francesca Farina; Marina POPOVA; Sofia ZOMPI; Ernesta Audisio; Marie-Pierre Ledoux; Luisa VERGA; Barbora Weinbergerova; Tomas Szotkowski; Maria Silva; Nicola Stefano Fracchiolla; Nick DE JONGE; Graham Collins; Monia Marchetti; Gabriele MAGLIANO; Carolina GARCÍA-VIDAL; Monika M. BIERNAT; Jaap van Doesum; Marina MACHADO; Fatih Demirkan; Murtadha Al Khabori; Pavel Zak; Benjamin Visek; Igor STOMA; Gustavo-Adolfo MÉNDEZ; Johan Maertens; Nina KHANNA; Ildefonso Espigado; Giulia DRAGONETTI; Luana Fianchi; Maria Ilaria Del Principe; Alba CABIRTA; Irati ORMAZABAL-VÉLEZ; Ozren Jaksic; Caterina BUQUICCHIO; Valentina BONUOMO; Josip Batinić; Ali S. OMRANI; Sylvain Lamure; Olimpia Finizio; Noemí FERNÁNDEZ; Iker FALCES-ROMERO; Ola BLENNOW; Rui BERGANTIM; Natasha Ali; Sein WIN; Jens VAN PRAET; Maria Chiara Tisi; Ayten SHIRINOVA; Martin SCHÖNLEIN; Juergen PRATTES; Monica PIEDIMONTE; Verena Petzer; Milan NAVRÁTIL; Austin Kulasekararaj; Pavel Jindra; Jiří SRAMEK; Andreas Glenthøj; Rita FAZZI; Cristina de Ramón; Chiara Cattaneo; Maria CALBACHO; Nathan C. BAHR; Shaimaa Saber EL-ASHWL; Raúl Córdoba; Michaela HANAKOVA; Giovanni ZAMBROTTA; Mariarita Sciumè; Stephen Booth; Raquel NUNES-RODRIGUES; Maria Vittoria SACCHI; Nicole GARCÍA-POUTÓN; Juan-Alberto MARTÍN-GONZÁLEZ; Sofya KHOSTELIDI; Stefanie GRÄFE; Laman RAHIMLI; alessandro busca; Paolo Corradini; Martin HOENIGL; Nikolai KLIMKO; Philipp Koehler; Antonio PAGLIUCA; Francesco Passamonti; Oliver Cornely; Livio pagano.
researchsquare; 2022.
Препринт в английский | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-1323457.v1

Реферат

Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died. Death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%). Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed. Patients with COVID-19 diagnosis between January and August 2020 had a significantly lower survival. COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment.


Тема - темы
COVID-19
4.
medrxiv; 2021.
Препринт в английский | medRxiv | ID: ppzbmed-10.1101.2021.03.24.21252687

Реферат

The COVID-19 pandemic has disrupted life throughout the world. Newly developed vaccines promise relief to people who live in high-income countries, although vaccines and expensive new treatments are unlikely to arrive in time to help people who live in low-and middle-income countries. The pathogenesis of COVID-19 is characterized by endothelial dysfunction. Several widely available drugs like statins, ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have immunometabolic activities that (among other things) maintain or restore endothelial cell function. For this reason, we undertook an observational study in four Belgian hospitals to determine whether in-hospital treatment with these drugs could improve survival in 959 COVID-19 patients. We found that treatment with statins and ACEIs/ARBs reduced 28-day mortality in hospitalized COVID-19 patients. Moreover, combination treatment with these drugs resulted in a 3-fold reduction in the odds of hospital mortality (OR=0.33; 95% CI 0.17-0.69). These findings were in general agreement with other published studies. Additional observational studies and clinical trials are needed to convincingly show that in-hospital treatment with statins, ACEIs/ARBs, and especially their combination saves lives.


Тема - темы
COVID-19
Критерии поиска